This study is looking at a potential new medication for chronic hepatitis B called Selgantolimod.
The purpose of this study is to understand the interaction between this medication and two already approved medications. These approved medications, called Omeprazole and Famotidine, decrease stomach acid production and are commonly used to treat reflux disease. For the initial stage of research into this medication, we require healthy participants with no medical conditions. This is so we can look at how the body metabolises the medications when taken together.